Literature DB >> 2423342

Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man.

W Krause, T Krais.   

Abstract

Plasma levels of the prostacyclin analogue, iloprost, were measured by antibody/GC/MS in healthy male volunteers given 1 and 3 ng/kg per min i.v. for 45 min, and 1 microgram/kg p.o. Following i.v. infusion, the steady-state plasma levels of iloprost were strictly dose-dependent (46 +/- 8 pg/ml and 135 +/- 24 pg/ml). The disposition was biphasic with half-lives of 3-4 min and 0.5 h. After oral administration, absorption of the drug was extremely rapid, the maximum plasma level of 251 +/- 32 pg/ml being achieved after 10 +/- 6 min. The bioavailability was 16 +/- 4%. Platelet aggregation induced by 2 microM ADP was reduced by 53% and 68% at the end of the two different infusions, and by 68% 15 min after p.o. administration. The ex-vivo inhibition of platelet aggregation by iloprost was not affected by preceding drug treatment. The cAMP content of platelets was increased by a factor of 2.5 at the end of the infusions and to a lesser extent 15 min after oral dosing. A slight increase in heart rate occurred during the infusion and within 30 min after oral administration; blood pressure was virtually unaffected. Except for transient side-effects (facial flush and headache) no adverse reactions were observed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423342     DOI: 10.1007/bf00614197

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  13 in total

1.  The antiplatelet and cardiovascular actions of a new carbacyclin derivative (ZK 36 374)--equipotent to PGI2 in vitro.

Authors:  K Schrör; H Darius; R Matzky; R Ohlendorf
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-06       Impact factor: 3.000

2.  [Significance of prostaglandins in arterial thrombosis pathology: survey of an ongoing experience].

Authors:  A Duvivier; J L David
Journal:  Rev Med Liege       Date:  1984-05-01

3.  Pharmacological effects of iloprost (ZK 36 374), a stable prostacyclin analogue, in man.

Authors:  P Ylitalo; S Kaukinen; E Seppäla; A K Nurmi; T Pessi; T Krais; H Vapaatalo
Journal:  Biomed Biochim Acta       Date:  1984

4.  Modulation of human platelet adenylate cyclase by prostacyclin (PGX).

Authors:  R R Gorman; S Bunting; O V Miller
Journal:  Prostaglandins       Date:  1977-03

5.  Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets.

Authors:  J E Tateson; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1977-03

6.  Pharmacokinetics and biotransformation of the prostacyclin analogue, ZK 36 374. III. Development of a radioimmunoassay and its application to the pharmacokinetics of ZK 36 374 in the rat.

Authors:  W Krause; B Nieuweboer
Journal:  Prostaglandins Leukot Med       Date:  1983-03

7.  Evidence for a direct stimulatory effect of prostacyclin on renin release in man.

Authors:  C Patrono; F Pugliese; G Ciabattoni; P Patrignani; A Maseri; S Chierchia; B A Peskar; G A Cinotti; B M Simonetti; A Pierucci
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

8.  Prostacyclin is not a circulating hormone.

Authors:  E Christ-Hazelhof; D H Nugteren
Journal:  Prostaglandins       Date:  1981-11

9.  Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3':5'-cyclic monophosphate levels.

Authors:  J L Data; B A Molony; M M Meinzinger; R R Gorman
Journal:  Circulation       Date:  1981-07       Impact factor: 29.690

10.  Biotransformation of the stable prostacyclin analogue, iloprost, in the rat.

Authors:  W Krause; M Hümpel; G A Hoyer
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

View more
  21 in total

1.  Pharmacokinetics and pharmacodynamics of cicaprost in healthy volunteers after oral administration of 5 to 20 micrograms.

Authors:  M Hildebrand; T Staks; B Nieuweboer
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Pulmonary arterial hypertension: classification, diagnosis and contemporary management.

Authors:  D J Fox; R S Khattar
Journal:  Postgrad Med J       Date:  2006-11       Impact factor: 2.401

3.  Prolongation of filter life in continuous arterio-venous haemodialysis.

Authors:  J K Brierley; A Hutchinson
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

4.  Intravenous infusion of iloprost in arterial occlusive disease: dose-dependent effects on skin microcirculation.

Authors:  L Caspary; A Creutzig; K Alexander
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers.

Authors:  W Krause; T Krais
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Clinical effects of intravenous iloprost in patients with intermittent claudication.

Authors:  U Müller-Bühl; C Diehm; T Krais; R Zimmermann; H Mörl; H H Eckstein
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Commentary on a recent article-"A prostacyclin analogue, Iloprost, protects from bleomycin-induced fibrosis in mice" Zhu Y et al. Respir Res. 2010 Mar 20;11(1):34.

Authors:  Richard Stratton; Florence Newton
Journal:  J Cell Commun Signal       Date:  2010-10-01       Impact factor: 5.782

Review 8.  [Iloprost. Pharmacology and clinical application during surgery].

Authors:  W Wilhelm; U Grundmann
Journal:  Anaesthesist       Date:  2004-08       Impact factor: 1.041

Review 9.  Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.

Authors:  S M Grant; K L Goa
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

10.  Stabilization of standard platelet concentrates and minimization of the platelet storage lesion by a prostacyclin analogue.

Authors:  M Elias; A Heethuis; M Weggemans; V Bom; N Blom; R L McShine; M R Halie; C T Smit Sibinga
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.